Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning, morning. Today, we have a trio of interesting studies on cholesterol reduction from the American Heart Association’s meeting in New Orleans. Also, Pfizer wins the Metsera deal with $10 billion, and we look at Trump’s GLP-1 deal more closely.
The need-to-know this morning
- Cogent Biosciences said its experimental drug, called bezuclastinib, lowered the risk of tumor progression or death by 50% compared to a standard treatment for advanced gastrointestinal stromal tumors — meeting the primary goal of a Phase 3 study.
How impactful could Trump’s GLP-1 deal be?
President Trump’s GLP-1 deal with Novo Nordisk and Eli Lilly last week marked a major policy shift that will finally allow Medicare to cover obesity treatments for high-risk patients.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply